References are numbered in consecutive order in the text, tables, or figures.
Use superscript arabic numerals to cite material, e.g., 1 The first reference used in a written document is listed as 1 in the reference list.
Where to place the superscript? The superscript number 1 is inserted into the document immediately next to the fact, concept, or quotation being cited. If citing more than one reference at the same point, separate the numbers with commas and no spaces between.
The Superscript number is inserted:
If a reference is used multiple times in one paper, use the same number throughout.
At the end of the document, include a reference list with full citations to each item. Name it References. Order citations as they appear in your paper.
Using author's names in-text: You may use author names in your text, as long as these mentions are accompanied by numbered citations. Use last names only. For items with one or two authors, include both names. For items with 3 or more authors, include the first author's surname and then 'et al' or 'and colleagues'.
Ex. Smith and Jones2 reported on the questionnaire. Ex. Hammersmith et al3 reported on the survey.
The AMA Manual. section 3.13.10 Secondary citations, states: Reference may be made to one author’s citation of, or quotation from, another’s work. Distinguish between citation and quotation (ie, between work mentioned and words actually quoted). In the text, the name of the original author, rather than the secondary source, should be mentioned. (See also 3.11.12, References to Print Journals, Discussants.) As with citation of an abstract of an article rather than citation of the original document (see 3.11.9, References to Print Journals, Abstracts and Other Material Taken From Another Source), citation of the original document is preferred unless it is not readily available. Only items actually consulted should be listed.
Ex. Cauley JA, Lui L-Y, Ensrud KE, et al. Osteoporosis and fracture risk in women of different ethnic groups. JAMA. 2005;293(17):2102-2108. Cited by: Acheson LS. Bone density and the risk of fractures: should treatment thresholds vary by race [editorial]? JAMA. 2005;293(17):2151-2154.
Finding treatments for breast cancer is a major goal for scientists.1,2 Some classes of drugs show more promise than others. Gradishar evaluated taxanes as a class.3 Other scientists have investigated individual drugs within this class, including Andre and Zielinski 2 and Joensuu and Gligorov. 4 Mita et al's investigation of cabazitaxel 5 seems to indicate a new role for this class of drugs.
1. Cancer Research Funding. National Cancer Institute. http://www.cancer.gov.offcampus.lib.washington.edu/cancertopics/factsheet/NCI/research-funding. Publication date unavailable. Updated June 6, 2011. Accessed November 3, 2012.
2. Andre F, Zielinski CC. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol. 2012;23(Suppl 2):vi46-vi51.
3. Gradishar WJ. Taxanes for the treatment of metastatic breast cancer. Breast Cancer (Auckl.). 2012;6:159-171.
4. Joensuu H, Gligorov J. Adjuvant treatments for triple-negative breast cancers. Ann Oncol. 2012;Suppl 6:vi40-45.
5. Mita AC, Figlin R, Mita MM. Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer? Clin Cancer Res. 2012;18(24):OF1-OF6.
Adapted from USC Norris Medical Library AMA:Citing Your Sources